Fundraising FoxPraeventix
Exton, US · Founded 2022 · Delaware corporation
Find your way into Praeventix
Sign up to see every warm intro you have to Praeventix
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Praeventix team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Praeventix is an early-stage biopharmaceutical company developing serotonergic (5-HT7 receptor) therapeutics, with a lead topical candidate PRA-523 aimed at treating chronic pruritus in conditions such as atopic dermatitis. It is also researching 5-HT7 modulators for inflammatory bowel disease and cocaine use disorder.
Founders & leadership
Praeventix was founded in 2022 by Douglas Pippin.
DP
Douglas PippinPresident & Founder, PIDouglas Pippin is President and Founder of Praeventix, a biopharmaceutical company developing serotonergic therapeutics, and has previously founded or co-founded multiple companies in drug discovery, dermatology, and green chemistry; his drug research background spans 15+ years focused on structure-based design and G-protein-coupled receptor ligands, with prior work contributing to a $500M+ pharmaceutical alliance and an anti-oncogenic compound that reached Phase II development.
HK
Heidi KempinskiExecutiveHeidi Kempinski is Executive Officer and Director at Praeventix, an early-stage biopharmaceutical company developing serotonergic therapeutics for conditions including atopic dermatitis, inflammatory bowel disease, and cocaine use disorder. She has held senior executive roles in startup and growth-stage biopharmaceutical organizations, with experience in drug development, R&D operations, corporate strategy, and mergers and acquisitions.
LO
Leon O. Moulder, Jr.Executive
K
KempinskiCEO
M
MoulderExecutive Chair
Board
RS
Robert S. HankinBoard director
LO
Leonard O. Moulder, Jr.Board director
Reported raises · per SEC filings
Form D private placements$16.7M disclosed across 3 rounds · 2022–2026
▶$5.6MraisedSep 2026 · 9 investors · BiotechnologyRule 506(b)
▶$5.6MraisedSep 2026 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Douglas A. Pippin, PhDExecutive Officer, Director
- Leon O. MoulderDirector
- Heidi KempinskiExecutive Officer, Director
- Robert S. HankinDirector
- Offering amount
- $5.6M
- Amount sold
- $5.6M
- First sale
- Feb 2026
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
▶$6.8MraisedMay 2025 · 9 investors · BiotechnologyRule 506(b)
▶$6.8MraisedMay 2025 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Heidi KempinskiExecutive Officer, Director
- Douglas A. PippinExecutive Officer, Director
- Robert S. HankinDirector
- Leonard O. Moulder, Jr.Director
- Offering amount
- $6.8M
- Amount sold
- $6.8M
- First sale
- May 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.3MraisedMay 2024 · 3 investors · BiotechnologyRule 506(b)
▶$4.3MraisedMay 2024 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Douglas A. PippinExecutive Officer, Director
- Leon O. Moulder, Jr.Director
- Offering amount
- $4.3M
- Amount sold
- $4.3M
- Proceeds to insiders
- $1.3M
- First sale
- Oct 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as Praeventix.
Frequently asked questions
- What does Praeventix do?
- Praeventix is an early-stage biopharmaceutical company developing serotonergic (5-HT7 receptor) therapeutics, with a lead topical candidate PRA-523 aimed at treating chronic pruritus in conditions such as atopic dermatitis. It is also researching 5-HT7 modulators for inflammatory bowel disease and cocaine use disorder.
- Who founded Praeventix?
- Praeventix was founded by Douglas Pippin in 2022.
- How much funding has Praeventix raised?
- Praeventix has disclosed $16.7M raised across 3 rounds.
- Where is Praeventix headquartered?
- Praeventix is headquartered in Exton, US.